Beigene (NASDAQ:BGNE) and Avenue Therapeutics (NASDAQ:ATXI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Insider and Institutional Ownership
77.8% of Beigene shares are owned by institutional investors. Comparatively, 2.1% of Avenue Therapeutics shares are owned by institutional investors. 14.1% of Beigene shares are owned by insiders. Comparatively, 5.0% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Beigene has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -1.21, meaning that its share price is 221% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Beigene and Avenue Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beigene currently has a consensus price target of $185.82, suggesting a potential upside of 67.88%. Avenue Therapeutics has a consensus price target of $9.50, suggesting a potential upside of 173.78%. Given Avenue Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Avenue Therapeutics is more favorable than Beigene.
Valuation & Earnings
This table compares Beigene and Avenue Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Beigene||$238.39 million||24.96||-$93.10 million||($2.23)||-49.64|
|Avenue Therapeutics||N/A||N/A||-$12.25 million||($1.77)||-1.96|
Avenue Therapeutics has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Beigene and Avenue Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Beigene beats Avenue Therapeutics on 7 of the 13 factors compared between the two stocks.
Beigene Company Profile
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.